Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Elliquis

- PMLiVE

Pfizer and BioNTech’s COVID-19 vaccine begins EMA evaluation

Vaccine is the second to undergo EMA's 'rolling review' process after AstraZeneca/Oxford Uni's candidate

- PMLiVE

Researchers call on Pfizer to delay COVID-19 vaccine application

Reports that the company could seek regulatory approval in October have raised safety concerns

- PMLiVE

FDA sets January decision date for Xalkori in ALK-positive lymphoma

FDA submission is based on results from ADVL0912 and A8081013 studies

- PMLiVE

FDA hands BMS and bluebird bio a priority review for ide-cel

Updated review accepted after refuse-to-file letter was issued in May

- PMLiVE

Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial

Results showing that the drug is an improvement on Xalkori were released at ESMO 2020 virtual congress

- PMLiVE

BMS eyes approval for second Opdivo combo in kidney cancer

Detailed results presented at ESMO 2020 virtual congress

- PMLiVE

BioNTech bolsters COVID-19 vaccine capacity with Novartis deal

Deal will expand production capacity for BNT162b2 candidate

- PMLiVE

Novavax CEO anticipates filing COVID-19 vaccine for approval in December

Pfizer also announces over 50% enrolment in COVID-19 vaccine trial

- PMLiVE

Pifzer, BioNTech eye October approval for mRNA-based COVID-19 vaccine

Companies share additional phase 1 safety and tolerability data

- PMLiVE

BMS pays $475m for Dragonfly’s IL-12 immunotherapy programme

Agreement will focus on development in oncology and haematology

- PMLiVE

BMS pledges $300m to tackle health inequity and improve diversity

Drugmaker announces a series of commitments to expand inclusion

- PMLiVE

Bristol-Myers Squibb’s revenues rise on Celgene acquisition

Sales of immunotherapy Opdivo decreased due to COVID-19 impact

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links